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Introduction {#cam41259-sec-0001}
============

The incidence of pneumonia in cancer patients is high due to impaired immune function caused by cancer itself and chemotherapy [1](#cam41259-bib-0001){ref-type="ref"}. In addition, surgery, a treatment modality for cancer, can cause additional lung injury [2](#cam41259-bib-0002){ref-type="ref"} which may make cancer patients be more susceptible to the development of pneumonia. Therefore, many authorities recommend pneumococcal and influenza vaccination in cancer patients [3](#cam41259-bib-0003){ref-type="ref"}. However, these recommendations are not based on clinical data regarding the incidence of pneumonia in various cancer patients and the specific type of pneumonia. Actually, there are limited data on the incidence of postoperative pneumonia (POP) following major cancer surgery. The incidence of POP after lung cancer surgery ranged from 2.1% to 10.7% [4](#cam41259-bib-0004){ref-type="ref"}, [5](#cam41259-bib-0005){ref-type="ref"}, [6](#cam41259-bib-0006){ref-type="ref"}, [7](#cam41259-bib-0007){ref-type="ref"}, [8](#cam41259-bib-0008){ref-type="ref"}, [9](#cam41259-bib-0009){ref-type="ref"}, [10](#cam41259-bib-0010){ref-type="ref"}, [11](#cam41259-bib-0011){ref-type="ref"}, after gastric cancer surgery 3.6% to 4.3% [12](#cam41259-bib-0012){ref-type="ref"}, [13](#cam41259-bib-0013){ref-type="ref"}, and after colorectal cancer surgery 6.2% [14](#cam41259-bib-0014){ref-type="ref"}. To our knowledge, however, there have been few studies conducted on the incidence of POP after surgery in other cancers or comparative analyses of the incidence of various cancer types. Therefore, a comparison of the incidence of POP in various common cancer patients and the identification of risk factors for POP provides important information to build vaccine priority and other preventive strategies. Therefore, our aim was to determine the incidence and risk factors of POP within 1 year after cancer surgery in patients with the five most common cancers (gastric, colorectal, lung, breast cancer, and hepatocellular carcinoma \[HCC\]) at five nationwide cancer centers in South Korea.

Methods {#cam41259-sec-0002}
=======

Study design and population {#cam41259-sec-0003}
---------------------------

We conducted a retrospective observational study at five nationwide cancer centers (Asan Medical Center, a 2700‐bed tertiary referral center located in Seoul; Samsung Medical Center, a 1950‐bed tertiary referral center in Seoul; Gachon University Gil Medical Center, a 1400‐bed tertiary referral center in Incheon; Ulsan University Hospital, 940‐bed tertiary referral center in Ulsan; and Hwasun Chonnam National University Hospital, a 700‐bed tertiary referral center in Gwangju in South Korea). Cancer and subsequent cancer surgery were considered exposure factors. We aimed to determine the overall incidence of POP in cancer patients who met the following inclusion criteria of this study: (1) adults (≥19 years old); (2) principal diagnosis of gastric cancer, colorectal cancer, lung cancer, breast cancer, or HCC; and (3) underwent cancer surgery from January 2014 to December 2014, within 6 months after cancer diagnosis. Cancer patients who participated in other clinical trials were excluded from this study because the administration of new chemotherapy or immunomodulating agents may affect the immunity and incidence of POP. Allocations of the number of patients in each center were according to the number of cancer surgeries performed in each center. The patients were randomly selected according to the allocated number of each center. The site investigators gathered the data from the medical records of patients from April to August 2016. The study protocols were approved by the independent institutional review board at each study site.

Definition {#cam41259-sec-0004}
----------

Diagnosis of pneumonia was established based on the ICD‐10 diagnostic code at a hospital discharge record and confirmed by the investigator upon identifying the presence of a new or progressive infiltrate on chest radiography or computed tomography, together with any of the following: new onset of purulent sputum, change in character of chronic sputum, fever ≥38°C, a new rise in C‐reactive protein value or WBC count, positive blood cultures, or isolation of pathogen from sputum, transtracheal aspirate or bronchial washing. Community‐acquired pneumonia was defined as pneumonia that occurs \<48 h after admission if the patient did not have contact with health care, and hospital‐acquired pneumonia (HAP) is defined as pneumonia that occurs 48 h or more after admission. Healthcare‐associated pneumonia (HCAP) is defined as pneumonia in patients who were hospitalized in an acute care hospital for two or more days within 90 days of the infection; resided in a nursing home or long‐term care facility; received recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection; or attended a hospital or hemodialysis clinic [15](#cam41259-bib-0015){ref-type="ref"}.

Data collection {#cam41259-sec-0005}
---------------

Demographic characteristics (age, sex, body mass index, and smoking history), comorbidity, history of previous surgery or pneumonia, results of pulmonary function test before surgery, previous vaccinations, type and stage of cancer, receipt of neoadjuvant or adjuvant therapy, date of diagnosis of cancer and surgery, duration of anesthesia and surgery, the amount of bleeding during surgery, and development of POP were retrospectively collected from the medical records. A bacterial pathogen was determined to be present if Gram‐positive or Gram‐negative bacteria were detected in blood, sputum, endotracheal aspirate, bronchoalveolar lavage specimen by culture or PCR assay; if *Chlamydia pneumoniae* or *Mycoplasma pneumoniae* was detected in a nasopharyngeal or oropharyngeal swab by means of PCR assay; if *Legionella pneumophila* was detected in sputum by means of PCR assay; or if *L. pneumophila* or *Streptococcus pneumoniae* was detected in urine by means of antigen detection[16](#cam41259-bib-0016){ref-type="ref"}. A viral pathogen was determined to be present if adenovirus, coronavirus, human metapneumovirus, human rhinovirus, influenza virus, parainfluenza virus, or respiratory syncytial virus was detected in a nasopharyngeal or oropharyngeal swab by means of PCR assay [16](#cam41259-bib-0016){ref-type="ref"}.

Statistical analysis {#cam41259-sec-0006}
--------------------

According to the annual report of the Korea Central Cancer Registry in 2002, 31,808 patients underwent cancer surgery due to solid cancer in 2002 [17](#cam41259-bib-0017){ref-type="ref"}. A previous study showed that the incidence of POP after operation for lung cancer was 3.6% [8](#cam41259-bib-0008){ref-type="ref"}. A total of 2000 patients was, therefore, projected to estimate the POP incidence with an error margin of ±0.8% using a two‐sided 95% confidence interval with the finite population of approximately 31,800 patients [18](#cam41259-bib-0018){ref-type="ref"}. The number of patients recruited was proportionately assigned to each of the hospitals according to their cancer surgery volume. Demographic and clinical characteristics of study subjects were summarized as mean (SD) or number of subjects (its percentage). One‐year cumulative incidence of POP was estimated using Kaplan--Meier analysis. An univariate Cox\'s proportional hazard (PH) regression analysis was performed to identify potential risk factors for POP incidence in cancer patients. Variables with *P* \< 0.05 were included in multiple Cox\'s PH regression model to identify independent risk factors associated with the incidence. The development of POP in patients with lung cancer may be associated with lung cancer surgery itself, and we assumed that the risk factors for POP in patients with other cancers may be different with that in patients with lung cancer. Therefore, we performed multivariable analyses to identify the risk factors in patients with lung cancer and non‐lung cancer, separately. Four multivariable models (using all patients with and without a variable of cancer type, using lung cancer patients only, using cancer patients other than lung cancer) were examined.

All statistical analyses were performed using the SAS software, version 9.4 (SAS Institute Inc., Cary, NC), and variables having a two‐sided *P *\< 0.05 were considered statistically significant.

Results {#cam41259-sec-0007}
=======

Patient characteristics {#cam41259-sec-0008}
-----------------------

Of the 2000 patients, excluding 118 patients who were enrolled in other clinical trials, those with gastric cancer, colorectal cancer, lung cancer, breast cancer, and HCC were 497 (25%), 525 (26%), 277 (14%), 552 (28%), and 149 (7%), respectively. The mean ± SD age was 59 ± 12 years, and 48% of all patients were male (Table [1](#cam41259-tbl-0001){ref-type="table-wrap"}). The number of participants in the ever‐smoker group was 719 (36%), and the most common underlying disease was diabetes mellitus (14%) followed by mild liver disease (7%), and chronic pulmonary disease (5%). The mean ± SD Charlson comorbidity index (CCI) score was 0.4 ± 0.6. About half of all patients (1112 \[56%\]) received neoadjuvant or adjuvant chemotherapy or radiation therapy.

###### 

Demographic and clinical characteristics of the 2000 patients

  Characteristics                                      Summary statistic
  ---------------------------------------------------- -------------------
  Age (years), mean ± SD                               59 ± 12
  Old age (≥65 years)                                  711 (36)
  Male                                                 969 (48)
  BMI (kg/m^2^), mean ± SD                             24 ± 3
  Smoking history                                      719 (36)
  Comorbidity[a](#cam41259-note-0003){ref-type="fn"}   
  Diabetes mellitus                                    280 (14)
  Mild liver disease                                   143 (7)
  Chronic pulmonary disease                            97 (5)
  Metastatic solid tumor                               73 (4)
  Other solitary tumors                                56 (3)
  Cerebrovascular disease                              54 (3)
  Alcoholism                                           22 (1)
  Moderate‐to‐severe renal disease                     15 (0.8)
  Moderate‐to‐severe liver disease                     14 (0.7)
  Ulcer disease                                        14 (0.7)
  Dementia                                             9 (0.5)
  Myocardial infarction                                8 (0.4)
  CCI scores, mean ± SD                                0.4 ± 0.6
  Pneumonia history                                    35 (2)
  Operation history                                    975 (49)
  Initial pulmonary function test                      
  FEV~1~ \< 80% (*n* = 1601)                           304 (19)
  FEV~1~/FVC \< 70% (*n* = 1600)                       25 (2)
  DLco \< 80% (*n* = 302)                              109 (36)
  Cancer type                                          
  Breast cancer                                        552 (28)
  Colorectal cancer                                    525 (26)
  Gastric cancer                                       497 (25)
  Lung cancer                                          277 (14)
  Hepatocellular carcinoma                             149 (7)
  Cancer stage                                         
  Tumor size                                           
  T1                                                   892 (45)
  T2 or T3                                             944 (47)
  T4                                                   164 (8)
  Nodes involved                                       
  N0                                                   1415 (71)
  N1‐N3                                                585 (29)
  Metastasis                                           
  M0                                                   1900 (95)
  M1                                                   100 (5)
  Neoadjuvant or adjuvant therapy                      1112 (56)
  Duration of anesthesia (minutes), mean ± SD          206 ± 99
  Duration of operation (minutes), mean ± SD           173 ± 90
  Surgery                                              
  Video‐assisted (or laparoscopic) surgery             800 (40)
  Open surgery                                         1161 (58)
  Conversion from Video‐assisted to open surgery       33 (2)
  Amount of bleeding (mL), mean ± SD                   172 ± (283)
  Received RBC transfusion                             52 (3)
  Time to resume diet (hours), mean ± SD               51 ± 44
  Time to ambulation (hours), mean ± SD                35 ± 37
  Incidence of POP                                     39 (2)
  Time to development of POP (weeks), mean ± SD        14 ± 15
  Type of POP                                          
  Community‐acquired pneumonia                         8 (21)
  Healthcare‐associated pneumonia                      10 (26)
  Hospital‐acquired pneumonia                          21 (54)
  Ventilator‐associated pneumonia                      0 (0)
  Pathogen                                             
  *Staphylococcus aureus*                              5 (13)
  *Streptococcus pneumoniae*                           2 (5)
  *Acinetobacter baumanii*                             2 (5)
  *Pseudomonas aeruginosa*                             1 (3)
  Respiratory virus                                    4 (10)
  Influenza virus                                      2 (5)
  Rhinovirus                                           1 (3)
  Human metapneumovirus                                1 (3)
  Others                                               5 (13)
  Unidentified                                         23 (59)

Data are presented as the number (%) of patients unless indicated otherwise. SD, standard deviation; BMI, body mass index; CCI, Charlson comorbidity index; FEV~1~, force expiratory volume in 1 sec; FVC, force vital capacity; DC~LC~, diffusing capacity of the lung for carbon monoxide; RBC, red blood cell; POP, postoperative pneumonia.

Multiple response item.
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Pneumonia incidence {#cam41259-sec-0009}
-------------------

Thirty‐nine patients developed POP; the overall 1‐year cumulative incidence of POP was 1.96% (95% CI, 1.35--2.57) (Table [2](#cam41259-tbl-0002){ref-type="table-wrap"} and Fig. [1](#cam41259-fig-0001){ref-type="fig"}A). The 1‐year cumulative incidence in each cancer was as follows: lung 7.97%, gastric 1.82%, colorectal 0.96%, HCC 0.67%, and breast 0.36% (Table [2](#cam41259-tbl-0002){ref-type="table-wrap"}). Of the 39 cases with POP, 8 (21%) were classified as community‐acquired pneumonia, 10 (26%) were as healthcare‐associated pneumonia, and 21 (54%) were as hospital‐acquired pneumonia. The time to the development of POP after surgery stratified by the classification of pneumonia is shown in Figure [S1](#cam41259-sup-0001){ref-type="supplementary-material"}. The pathogen was identified in 13 of 39 (41%) patients; *Staphylococcus aureus* in five (13%) patients, *S. pneumoniae* in two (5%), *Acinetobacter baumanii* in two (5%), *Pseudomonas aeruginosa* in one (3%), and influenza virus in two (5%) patients (Table [1](#cam41259-tbl-0001){ref-type="table-wrap"}). Of the 39 patients, 18 were confirmed by chest CT as well. In addition, the overall 30‐day cumulative incidence of POP was 0.85% (95% CI, 0.45--1.25) and those in each cancer were as follows: 2.89% in lung cancer, 0.81% in gastric cancer, 0.76% in colorectal cancer, 0.67% in HCC, and 0% in breast cancer.

###### 

One‐year cumulative incidence of postoperative pneumonia with total patients as well as by cancer type

                             No. of patients   No. of POP   Estimated 1‐year cumulative incidence (%) (95% CI)[a](#cam41259-note-0005){ref-type="fn"}   HR (95% CI)[b](#cam41259-note-0006){ref-type="fn"}   *P*‐value
  -------------------------- ----------------- ------------ ------------------------------------------------------------------------------------------- ---------------------------------------------------- -----------
  Total                      2000              39           1.96 (1.35, 2.57)                                                                                                                                
  Lung cancer                277               22           7.97 (4.78, 11.17)                                                                          22.9 (5.38, 97.2)                                    \<0.0001
  Gastric cancer             497               9            1.82 (0.64, 3.01)                                                                           5.08 (1.10, 23.5)                                    0.04
  Colorectal cancer          525               5            0.96 (0.12, 1.79)                                                                           2.65 (0.51, 13.7)                                    0.61
  Hepatocellular carcinoma   149               1            0.67 (0.00, 1.98)                                                                           1.88 (0.17, 20.7)                                    0.24
  Breast cancer              552               2            0.36 (0.00, 0.86)                                                                           Reference                                            --

No, number; POP, postoperative pneumonia; CI, confidence interval; HR, hazard ratio.

By Kaplan--Meier analysis.

By univariable Cox\'s PH regression analysis.
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![One‐year cumulative incidence of postoperative pneumonia with total patients (A) as well as by cancer type (B) (*N* = 2000).](CAM4-7-261-g001){#cam41259-fig-0001}

As shown in Table [2](#cam41259-tbl-0002){ref-type="table-wrap"}, the HR (95% CI) for development of POP incidence in patients with lung cancer, gastric cancer, colorectal cancer, and HCC were 22.9 (5.38--97.2) (*P *\<* *0.0001), 5.08 (1.10--23.5) (*P *=* *0.04), 2.65 (0.51--13.7) (*P *=* *0.61) and 1.88 (0.17--20.7) (*P *=* *0.24), respectively, compared to those with breast cancer as a referent. The Kaplan--Meier analysis showed that patients with lung cancer developed POP more frequently than patients with other cancers (long‐rank *P *\<* *0.001; Fig. [1](#cam41259-fig-0001){ref-type="fig"}B). Interestingly, the cumulative incidence of POP in patients with gastric cancer was higher than the composite cumulative incidence of POP in patients with colorectal cancer, HCC, and breast cancer after 100 days from the surgery (log‐rank *P* = 0.03; Fig. [S2](#cam41259-sup-0001){ref-type="supplementary-material"}).

Risk factors for development of POP {#cam41259-sec-0010}
-----------------------------------

In univariable Cox regression analysis, the following variables were associated with POP: male, older age, smoker, higher CCI score, chronic pulmonary disease, ulcer disease, moderate‐to‐severe liver disease, previous pneumonia history, duration of operation, conversion from video‐associated surgery to open surgery, and more bleeding during the surgery (Table [3](#cam41259-tbl-0003){ref-type="table-wrap"}).

###### 

One‐year cumulative incidence of postoperative pneumonia according to patient\'s characteristics (*N* = 2000)

                                     No. of patients   No. of POP   Estimated 1‐year cumulative incidence (%) (95% CI)[a](#cam41259-note-0008){ref-type="fn"}   HR (95% CI)[b](#cam41259-note-0009){ref-type="fn"}   *P*‐value
  ---------------------------------- ----------------- ------------ ------------------------------------------------------------------------------------------- ---------------------------------------------------- -----------
  Gender                                                                                                                                                                                                             
  Male                               969               31           3.21 (2.10, 4.33)                                                                           4.19 (1.93, 9.11)                                    0.0003
  Female                             1031              8            0.78 (0.24, 1.31)                                                                           Ref                                                  --
  Age                                                                                                                                                                                                                
  ≥65 years                          711               26           3.68 (2.29, 5.07)                                                                           3.70 (1.90, 7.19)                                    0.0001
  \< 65 years                        1289              13           1.01 (0.46, 1.56)                                                                           Ref                                                  --
  BMI (kg/m^2^)                      1997              39                                                                                                       0.96 (0.87, 1.06)                                    0.46
  Smoking history                                                                                                                                                                                                    
  Ever smoker                        719               29           4.05 (2.61, 5.5)                                                                            5.2 (2.53, 10.7)                                     \<0.0001
  Never smoker                       1264              10           0.79 (0.30, 1.28)                                                                           Ref                                                  --
  CCI scores                         2000              39                                                                                                       2.91 (1.96, 4.33)                                    \<0.0001
  Chronic pulmonary disease                                                                                                                                                                                          
  Yes                                97                8            8.27 (2.78, 13.76)                                                                          5.22 (2.40, 11.4)                                    \<0.0001
  No                                 1903              31           1.64 (1.06, 2.21)                                                                           Ref                                                  --
  Ulcer disease                                                                                                                                                                                                      
  Yes                                14                2            14.29 (0.00, 32.62)                                                                         8.41 (2.03, 34.9)                                    0.003
  No                                 1986              37           1.87 (1.27, 2.47)                                                                           Ref                                                  --
  Moderate‐to‐severe liver disease                                                                                                                                                                                   
  Yes                                14                2            14.29 (0.00, 32.62)                                                                         8.03 (1.94, 33.3)                                    0.004
  No                                 1986              37           1.87 (1.27, 2.47)                                                                           Ref                                                  --
  Pneumonia history                                                                                                                                                                                                  
  Yes                                35                4            11.61 (0.91, 22.31)                                                                         6.50 (2.31, 18.3)                                    0.004
  No                                 1883              34           1.81 (1.21, 2.41)                                                                           Ref                                                  --
  Neoadjuvant or adjuvant therapy                                                                                                                                                                                    
  Yes                                1112              23           2.08 (1.24, 2.92)                                                                           1.1 (0.6, 2.2)                                       0.68
  No                                 888               16           1.81 (0.93, 2.68)                                                                           Ref                                                  --
  Duration of the operation (min)    2000              39                                                                                                       1.003 (1.0, 1.005)                                   0.003
  Duration of the anesthesia (min)   1996              39                                                                                                       1.002 (1.0, 1.005)                                   0.06
  Open surgery                       1161              22           1.91 (1.12, 2.69)                                                                           1.09 (0.56, 2.12)                                    0.81
  Conversions                        33                3            9.09 (0.0, 18.9)                                                                            5.38 (1.55, 18.7)                                    0.01
  Video‐assisted operation           800               14           1.75 (0.84, 2.66)                                                                           Ref                                                  --
  Amount of bleeding (ml)            1572              30                                                                                                       1.001 (1.0, 1.001)                                   0.01
  Time to resume diet (hours)        1937              39                                                                                                       0.99 (0.98, 1.0)                                     0.08
  Time to ambulation (hours)         1027              24                                                                                                       1.01 (1.0, 1.01)                                     0.09

No, number; POP, postoperative pneumonia; CI, confidence interval; HR, hazard ratio; Ref, reference; OP, operation; min, minutes; CCI, Charlson comorbidity index.

By Kaplan--Meier analysis.

By univariable Cox\'s PH regression analysis.

John Wiley & Sons, Ltd

Table [4](#cam41259-tbl-0004){ref-type="table-wrap"} demonstrates the multiple analysis of risk factors for the development of POP. The significant variables in the univariable analysis were included in a multiple Cox\'s PH regression model 1; this model indicated that older age, smoker, higher scores of CCI, ulcer disease, and pneumonia history were independent risk factors for development of POP among all patients. Model 2 included significant variables in the univariable analysis and cancer type as an independent variable; higher score of CCI, moderate‐to‐severe liver disease, and lung cancer were independent risk factors for development of POP. In addition, in patients with lung cancer, smoker, higher scores of CCI, and moderate‐to‐severe liver disease were associated with the development of POP (model 3). Finally, in patients with other cancers, chronic pulmonary disease was associated with the development of POP (model 4).

###### 

Risk factors for an incidence of postoperative pneumonia among patients with cancer

                                                  Model 1                                                        Model 2                                                        Model 3                                                          Model 4
  ----------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------
  Male (Ref: female)                              0.814 (0.265, 2.506)                                           1.084 (0.314, 3.74)                                            0.453 (0.071, 2.903)                                             1.355 (0.295, 6.221)
  Old age (≥65 years) (Ref: \<65)                 3.158 (1.567, 6.364)[b](#cam41259-note-0012){ref-type="fn"}    2.031 (0.988, 4.175)                                           1.086 (0.417, 2.827)                                             2.903 (0.963, 8.745)
  Smoking history                                 4.627 (1.661, 12.892)[b](#cam41259-note-0012){ref-type="fn"}   2.43 (0.789, 7.481)                                            10.141 (1.127, 91.224)[b](#cam41259-note-0012){ref-type="fn"}    1.796 (0.47, 6.738)
  CCI score                                       2.035 (1.242, 3.333)[b](#cam41259-note-0012){ref-type="fn"}    2.265 (1.392, 3.683)[b](#cam41259-note-0012){ref-type="fn"}    2.879 (1.527, 5.429)[b](#cam41259-note-0012){ref-type="fn"}      1.294 (0.549, 3.052)
  Chronic pulmonary disease                       1.153 (0.474, 2.803)                                           1.133 (0.469, 2.74)                                            0.351 (0.078, 1.587)                                             5.011 (1.439, 17.454)[b](#cam41259-note-0012){ref-type="fn"}
  Ulcer disease                                   6.244 (1.407, 27.713)[b](#cam41259-note-0012){ref-type="fn"}   3.977 (0.911, 17.368)                                          4.989 (0.643, 38.698)                                            6.594 (0.645, 67.404)
  Moderate‐to‐severe liver disease                3.67 (0.757, 17.797)                                           5.049 (1.005, 25.364)[b](#cam41259-note-0012){ref-type="fn"}   23.561 (1.162, 477.545)[b](#cam41259-note-0012){ref-type="fn"}   6.313 (0.58, 68.767)
  Pneumonia history                               3.012 (1.051, 8.629)[b](#cam41259-note-0012){ref-type="fn"}    1.215 (0.398, 3.708)                                           0.794 (0.205, 3.08)                                              
  Lung cancer (Ref: breast cancer)                                                                               5.431 (1.014, 29.08)[b](#cam41259-note-0012){ref-type="fn"}                                                                     
  Gastric cancer (Ref: breast cancer)                                                                            1.416 (0.245, 8.186)                                                                                                            
  Hepatocellular carcinoma (Ref: breast cancer)                                                                  0.3 (0.022, 4.14)                                                                                                               
  Colorectal cancer (Ref: breast cancer)                                                                         0.789 (0.129, 4.839)                                                                                                            
  Duration of the operation (min)                 1.001 (0.998, 1.004)                                           1.002 (0.998, 1.006)                                           1.006 (0.999, 1.012)                                             1 (0.995, 1.005)

Model 1: with all patients; Model 2: with all patients without considering cancer type as an independent variable; Model 3: with lung cancer patients only; Model 4: with the other cancer patients. In model 4, variable of pneumonia history was excluded from the model due to its nonconvergence. HR, hazard ratio; CI, confidence interval; Ref, reference; CCI, Charlson comorbidity index; min, minutes.

By Multivariable Cox\'s PH regression analysis.

Variables with *P* \< 0.05.
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Discussion {#cam41259-sec-0011}
==========

In the present study, we observed that the 1‐year cumulative incidence of POP in the five most common cancers was 2% in South Korea. Of the selected cancers, the incidence of POP was highest in lung cancer. Older age, smoking history, higher CCI score, ulcer disease, and history of previous pneumonia were independent risk factors for development of POP in cancer patients.

The POP incidence in lung cancer in this study (8%) was within the range of that in previous reports (2.1--10.7%) [4](#cam41259-bib-0004){ref-type="ref"}, [5](#cam41259-bib-0005){ref-type="ref"}, [6](#cam41259-bib-0006){ref-type="ref"}, [7](#cam41259-bib-0007){ref-type="ref"}, [8](#cam41259-bib-0008){ref-type="ref"}, [9](#cam41259-bib-0009){ref-type="ref"}, [10](#cam41259-bib-0010){ref-type="ref"}, [11](#cam41259-bib-0011){ref-type="ref"}. However, the incidences of POP in patients with gastric cancer and colorectal cancer in the present study (1.8% and 0.96%) were lower than those in previous reports (3.6--4.3% for gastric cancer [12](#cam41259-bib-0012){ref-type="ref"}, [13](#cam41259-bib-0013){ref-type="ref"} and 6.2% for colorectal cancer [14](#cam41259-bib-0014){ref-type="ref"}). The reason for these discrepancies is not clear. The possible explanations may be difference of the characteristics of the study population, perioperative management, and the period of study. Study population in two previous Japanese studies identifying the incidence and risk factors of POP after gastric cancer surgery were older than our patients with gastric cancer (median age 68 years in the Japanese study vs. a mean age of 59 years in this study), and the durations of the operations in the previous studies [12](#cam41259-bib-0012){ref-type="ref"}, [13](#cam41259-bib-0013){ref-type="ref"} were longer than those in our study. The study identifying the incidence of POP in patients with colorectal cancer was conducted 20 years ago [14](#cam41259-bib-0014){ref-type="ref"}, and the increased proportion of laparoscopic surgery and improved perioperative management may be associated with the declined incidence of POP in colorectal cancer in the present study. Additionally, this is one of the few studies comparing the incidence of POP by cancer type. We have clearly shown that the incidence of POP was highest in lung cancer, followed by gastric cancer, colorectal cancer, HCC, and breast cancer. This finding may provide information on the policy of pneumococcal or influenza vaccination priority in common cancer; for example, patients with lung cancer are vaccinated in priority. However, the number of confirmed cases of pneumococcal and influenza pneumonia was small in this study, so some may argue that our data are insufficient to guide policy considerations. Despite of this, pneumococcal and influenza vaccines in cancer patients have been recommended in clinical practice [3](#cam41259-bib-0003){ref-type="ref"} although there was limited information on the specific type of pneumonia in cancer patients. Therefore, given the limited sensitivity of microbiologic diagnostic methods, our data should be interpreted with great caution to prioritize those patients who need vaccination.

Interestingly, the incidence of POP in patients with gastric cancer was higher than that in patients with colorectal cancer, HCC, and breast cancer at 100 days after cancer surgery (Fig. [S2](#cam41259-sup-0001){ref-type="supplementary-material"}). Aspiration of esophageal reflux contents, malnutrition, and decreased immunity could be responsible for this novel finding [19](#cam41259-bib-0019){ref-type="ref"}, [20](#cam41259-bib-0020){ref-type="ref"}, [21](#cam41259-bib-0021){ref-type="ref"}. Kaneda et al. showed a higher incidence of POP among patients who underwent lung cancer surgery with a history of gastrectomy [19](#cam41259-bib-0019){ref-type="ref"}. Similarly, the history of gastrectomy has been considered a risk factor for tuberculosis, suggesting that gastrectomy may affect cell‐mediated immunity [20](#cam41259-bib-0020){ref-type="ref"}, [21](#cam41259-bib-0021){ref-type="ref"}, [22](#cam41259-bib-0022){ref-type="ref"}. Further biologic plausibility for these findings should be addressed in future studies.

Various factors have been found to increase POP in previous studies; male gender [13](#cam41259-bib-0013){ref-type="ref"}, older age [5](#cam41259-bib-0005){ref-type="ref"}, [6](#cam41259-bib-0006){ref-type="ref"}, [7](#cam41259-bib-0007){ref-type="ref"}, [8](#cam41259-bib-0008){ref-type="ref"}, [10](#cam41259-bib-0010){ref-type="ref"}, [11](#cam41259-bib-0011){ref-type="ref"}, [12](#cam41259-bib-0012){ref-type="ref"}, [23](#cam41259-bib-0023){ref-type="ref"}, [24](#cam41259-bib-0024){ref-type="ref"}, obesity [8](#cam41259-bib-0008){ref-type="ref"}, malnutrition [24](#cam41259-bib-0024){ref-type="ref"}, previous pneumonia [8](#cam41259-bib-0008){ref-type="ref"}, diabetes mellitus [12](#cam41259-bib-0012){ref-type="ref"}, chronic pulmonary disease [8](#cam41259-bib-0008){ref-type="ref"}, alcoholism [8](#cam41259-bib-0008){ref-type="ref"}, atrial fibrillation [8](#cam41259-bib-0008){ref-type="ref"}, CCI score [6](#cam41259-bib-0006){ref-type="ref"}, type of surgery [6](#cam41259-bib-0006){ref-type="ref"}, [11](#cam41259-bib-0011){ref-type="ref"}, [23](#cam41259-bib-0023){ref-type="ref"}, [24](#cam41259-bib-0024){ref-type="ref"}, duration of surgery [23](#cam41259-bib-0023){ref-type="ref"}, pulmonary function test [5](#cam41259-bib-0005){ref-type="ref"}, [7](#cam41259-bib-0007){ref-type="ref"}, [11](#cam41259-bib-0011){ref-type="ref"}, [12](#cam41259-bib-0012){ref-type="ref"}, [23](#cam41259-bib-0023){ref-type="ref"}, perioperative transfusion [5](#cam41259-bib-0005){ref-type="ref"}, [12](#cam41259-bib-0012){ref-type="ref"}, [13](#cam41259-bib-0013){ref-type="ref"}, postoperative complication other than pneumonia [5](#cam41259-bib-0005){ref-type="ref"}, advanced cancer stage [24](#cam41259-bib-0024){ref-type="ref"}, and induction therapy [7](#cam41259-bib-0007){ref-type="ref"} were associated with POP development. In the present study, we showed that older age, smoker, higher CCI score, peptic ulcer disease, and history of previous pneumonia were independent risk factors for development of POP among all patients. The association of peptic ulcer disease and POP, although the number of patients with a history of peptic ulcer (*n* = 14) is too small to draw a firm conclusion, may be related to the use of proton‐pump inhibitor, which raises gastric pH resulting in an overgrowth of bacteria. There have been reports that the use of acid‐suppressive medication increased the risk for pneumonia [25](#cam41259-bib-0025){ref-type="ref"}, [26](#cam41259-bib-0026){ref-type="ref"}, [27](#cam41259-bib-0027){ref-type="ref"}. In addition, when the cancer type was included as variables in the multivariable analysis (model 2), we demonstrated that lung cancer itself was an independent risk factor after adjustment for other factors. Therefore, clinicians should be aware of the heightened risk of POP in patients with these risk factors and postoperative care including frequent coughing, deep breathing, early ambulation, and use of a spirometer [28](#cam41259-bib-0028){ref-type="ref"} cannot be overemphasized for preventing POP.

There are limitations of note in this study. First, since the diagnosis of pneumonia was established according to the ICD‐10 diagnostic code on each hospital\'s discharge record, the incidence of POP may be underreported. Second, the follow‐up period after cancer surgery was 1 year. Some may question that a 1‐year follow‐up period is arbitrary. We assumed that the development of POP is highest during the 1 year after surgery and then gradually becomes lower because surgery and perioperative chemoradiation therapy may affect the occurrence of pneumonia. However, further studies are warranted to obtain long‐term follow‐up data in cancer patients who received surgery. Third, since there were few incidences of POP in patients with HCC and breast cancer, our findings should be cautiously interpreted in these patients. Fourth, of the 30 patients who died during the follow‐up period, a total of 20 patients died without developing POP. As these patients were treated as a censoring event, not as a competing risk, there was a possibility of our estimate of hazard ratio for development of POP being slightly overestimated. Finally, the pathogen identification rate was low, and the incidence of pneumococcal pneumonia may be underreported. However, the pathogen is usually not detected in half of patients with pneumonia in clinical settings [29](#cam41259-bib-0029){ref-type="ref"}. In addition, the previous study evaluating the incidence and pathogens of community‐acquired pneumonia requiring hospitalization in adult patients showed that the pathogen was detected in only 38% of patients [16](#cam41259-bib-0016){ref-type="ref"}. In this context, the pathogen identification rate (41%) in the present study is in line with previous studies. Therefore, the low proportion of *S. pneumoniae* as an etiologic agent in POP should be cautiously interpreted due to the insensitivity of sputum culture.

In conclusion, the overall 1‐year cumulative incidence of POP was 2% in total patients with selected solid cancers, 8% in patients with lung cancer, and 2% in patients with gastric cancer in South Korea. Older age, higher CCI scores, smoker, ulcer disease, and previous pneumonia history were independent risk factors for the development of POP in cancer patients. Therefore, more cautious monitoring the development of POP in patients with these risk factors would be helpful.
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**Figure S1.** Time to development of POP after surgery stratified by types of pneumonia.

**Figure S2.** POP cumulative incidence in gastric cancer versus the composite POP cumulative incidence of colorectal cancer, hepatocellular carcinoma and breast cancer within 100 days from the surgery (A) and after 100 days from the surgery (B).
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Click here for additional data file.
